Therapeutic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics 2007. CA Cancer J Clin 2007; 57:43 - 66
   PubMed Web of Science ®Google Scholar
• Karamouzis MV, Grandis JR, Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. Jama 2007; 298:70 - 82
   PubMed Web of Science ®Google Scholar
• Yigitbasi OG, Younes MN, Doan D, et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004; 64:7977 - 7984
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006; 354:567 - 578
   PubMed Web of Science ®Google Scholar
• Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 2005; 105:4429 - 4436
   PubMed Web of Science ®Google Scholar
• Eggert A, Grotzer MA, Ikegaki N, et al. Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor. J Clin Oncol 2001; 19:689 - 696
   PubMed Web of Science ®Google Scholar
• Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res 2002; 62:6756 - 6763
   PubMed Web of Science ®Google Scholar
• Kupferman ME, Jiffar T, El-Naggar AK, et al. TrkB induces EMT and plays a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010;
   PubMed Web of Science ®Google Scholar
• Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430:1034 - 1039
   PubMed Web of Science ®Google Scholar
• Camoratto AM, Jani JP, Angeles TS, et al. CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. International Journal of Cancer 1997; 72:673 - 679
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573 - 584
   PubMed Web of Science ®Google Scholar
• Zhou G, Xie TX, Zhao M, et al. Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 2008; 27:3527 - 3538
   PubMed Web of Science ®Google Scholar
• Nakashima T, Pak SC, Silverman GA, Spring PM, Frederick MJ, Clayman GL. Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is downregulated in head and neck cancer cells. Biochimica et Biophysica Acta (BBA)—Gene Structure and Expression 2000; 1492:441 - 446
   PubMed Web of Science ®Google Scholar
• Wang T, Lamb ML, Scott DA, et al. Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases. Journal of Medicinal Chemistry 2008; 51:4672 - 4684
   PubMed Web of Science ®Google Scholar
• George DJ, Dionne CA, Jani J, et al. Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999; 59:2395 - 2401
   PubMed Web of Science ®Google Scholar
• Marshall JL, Kindler H, Deeken J, et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Investigational New Drugs 2005; 23:31 - 37
   PubMed Web of Science ®Google Scholar
• Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111:5663 - 5671
   PubMed Web of Science ®Google Scholar
• Wood ER, Kuyper L, Petrov KG, Hunter Iii RN, Harris PA, Lackey K. Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and azaoxindoles. Bioorganic & Medicinal Chemistry Letters 2004; 14:953 - 957
   PubMed Web of Science ®Google Scholar
• Lippa B, Morris J, Corbett M, et al. Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure-activity relationship, computer modeling, optimization and identification of highly potent antagonists. Bioorganic & Medicinal Chemistry Letters 2006; 16:3444 - 3448
   PubMed Web of Science ®Google Scholar
• Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324:1685 - 1690
   PubMed Web of Science ®Google Scholar
• Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798 - 1804
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M, et al. Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. N Engl J Med 2003; 349:2091 - 2098
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells. Clin Cancer Res 2005; 11:6924 - 6932
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B, et al. Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:3562 - 3567
   PubMed Web of Science ®Google Scholar
• Michaelis M, Bliss J, Arnold SC, et al. Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins. Clin Cancer Res 2008; 14:6531 - 6537
   PubMed Web of Science ®Google Scholar
• Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (â‘’)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Molecular Cancer Therapeutics 2005; 4:1096 - 1104
   PubMed Web of Science ®Google Scholar
• Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik upregulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Molecular Cancer Therapeutics 2008; 7:1647 - 1655
   PubMed Web of Science ®Google Scholar